First Trust Advisors LP lifted its stake in Mylan (NASDAQ:MYL) by 69.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,276,547 shares of the company’s stock after acquiring an additional 523,437 shares during the period. First Trust Advisors LP owned approximately 0.24% of Mylan worth $54,011,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Canada Pension Plan Investment Board boosted its stake in Mylan by 99.5% during the third quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock worth $38,189,000 after buying an additional 607,094 shares in the last quarter. FMR LLC boosted its stake in Mylan by 19.8% during the second quarter. FMR LLC now owns 813,267 shares of the company’s stock worth $31,572,000 after buying an additional 134,258 shares in the last quarter. Toronto Dominion Bank boosted its stake in Mylan by 28.2% during the third quarter. Toronto Dominion Bank now owns 200,017 shares of the company’s stock worth $6,274,000 after buying an additional 43,943 shares in the last quarter. Rhumbline Advisers boosted its stake in Mylan by 7.2% during the third quarter. Rhumbline Advisers now owns 791,463 shares of the company’s stock worth $24,828,000 after buying an additional 53,154 shares in the last quarter. Finally, Pzena Investment Management LLC boosted its stake in Mylan by 84.1% during the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after buying an additional 10,381,697 shares in the last quarter. Institutional investors and hedge funds own 75.56% of the company’s stock.
Shares of Mylan (NASDAQ MYL) opened at $42.14 on Friday. Mylan has a 52 week low of $29.39 and a 52 week high of $47.82. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The company has a market cap of $22,342.57, a price-to-earnings ratio of 26.17, a PEG ratio of 1.13 and a beta of 1.35.
In related news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is currently owned by insiders.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Deutsche Bank set a $50.00 price target on shares of Mylan and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Wells Fargo & Co set a $43.00 price target on shares of Mylan and gave the stock a “hold” rating in a research note on Thursday, January 18th. TheStreet upgraded shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Finally, Susquehanna Bancshares reiterated a “positive” rating and set a $55.00 price target (up previously from $47.00) on shares of Mylan in a research note on Thursday, January 25th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $44.89.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2018/02/17/mylan-myl-shares-bought-by-first-trust-advisors-lp.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.